Probstfield JL, et al. - Researchers performed an extended follow-up of AIM-HIGH participants to see if there would be any change in the previous results, which found no reduced cardiovascular (CV) events in association with extended-release niacin (ERN) among patients with atherogenic dyslipidemia who were on statin-based therapy. AIM-HIGH was a placebo-controlled trial including 3,414 patients with established CV disease, low baseline high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides (TG) levels randomized to ERN 1,500-2,000 mg/day vs placebo. The patients displayed no lowering of CV event rates with 3 years of ERN treatment. The findings were not altered after an additional year of follow-up off assigned treatment.